| Officer | Age | In this role | Joined | 2025 pay | Source |
|---|---|---|---|---|---|
|
William H. Lewis
Also a director
Chair and Chief Executive Officer
|
57 |
Since 2012
14 years
|
Not stated | $14,467,393 | |
|
Roger Adsett
Chief Operating Officer
|
57 |
Since 2019
7 years
|
2016 | $4,691,405 | |
|
Martina Flammer
Chief Medical Officer
|
62 |
Since 2019
7 years
|
2019 | $4,716,513 | |
|
S. Nicole Schaeffer
Chief People Strategy Officer
|
57 |
Since 2018
8 years
|
2013 | Not reported | |
|
Michael A. Smith
Chief Legal Officer
|
49 |
Since 2024
2 years
|
2014 | $4,138,160 | |
|
Samuele Butera
SVP, GM, Global Respiratory
Title from the Form 4 dated Jun 23, 2026
|
Not stated | Not stated | Not stated | Not reported | |
|
Patrick Kevin Kane
Corporate Controller
Title from the Form 3 dated Oct 30, 2026
|
Not stated | Not stated | Not stated | Not reported |
Each officer opens the passage of the filing that names them. A title that changed since the list comes from the officer's latest Form 3, 4 or 5, and its start year is not stated there. "Not stated" means the filing does not say. Pay is the proxy's Summary Compensation Table, which reports only the named executive officers.
From the proxy statement filed Apr 1, 2026 · updated by the 8-K of Oct 20, 2026
| Director | Age | On board | Independent | Committees | Other public boards | 2025 pay | Source |
|---|---|---|---|---|---|---|---|
|
William H. Lewis
Board chair, CEO
|
57 |
2012
14 years
|
Not stated | None stated | NewAmsterdam Pharma Company N.V. | Paid as CEO | |
|
David R. Brennan
Lead independent director
|
72 |
2014
12 years
|
Not stated |
Compensation · Chair
|
None stated | $465,000 | |
|
Elizabeth McKee Anderson
|
68 |
2018
8 years
|
Independent |
Audit
Nominations and Governance · Chair
|
GSK plc | $432,864 | |
|
Clarissa Desjardins, Ph.D.
|
59 |
2019
7 years
|
Independent |
Science and Technology · Chair
|
None stated | $425,000 | |
|
Leo Lee
|
56 |
2018
8 years
|
Independent |
Compensation
Science and Technology
|
None stated | $425,000 | |
|
Carol A. Schafer
|
62 |
2020
6 years
|
Not stated |
Audit
Nominations and Governance
|
Kura Oncology, Inc. | $427,500 | |
|
Melvin Sharoky, M.D.
|
75 |
2001
25 years
|
Not stated |
Nominations and Governance
Science and Technology
|
None stated | $425,000 | |
|
Paul Hudson
Joined Oct 19, 2026
|
- | - | - |
Compensation Committee
|
- | - | |
|
Utpal Koppikar
Joined Oct 19, 2026
|
- | - | - |
Audit Committee
|
- | - | |
|
David W.J. McGirr
Leaving at the meeting
|
71 |
2013
13 years
|
Independent |
Audit · Chair
|
None stated | $430,000 |
Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive. A director marked Joined was added by an 8-K; their row opens that 8-K, and a dash is a value it does not give.
The proxy filed Apr 1, 2026 states there were none.
Read it in the proxyLoading...